ImmunoGen Announces New License Agreement with Novartis - Novartis (NYSE:NVS)

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.

ImmunoGen (NASDAQ: IMGN) today announced that Novartis (NYSE: NVS) has licensed the exclusive right to use the Company's ADC technology to develop anticancer therapeutics to an undisclosed target. “We believe the therapies Novartis is developing with our ADC technology have the potential to make an important difference for patients,” commented Daniel Junius, President and CEO. This is the second license to be taken by Novartis under a 2010 agreement between the companies. For each license, ImmunoGen receives an upfront payment and is entitled to receive milestone payments potentially totaling approximately $200 million plus royalties on See full press release

20-Year Pro Trader Reveals His "MoneyLine"

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!